Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs

GLP-1 + Glucagon Co-infusion

MARKETED

GLP-1/glucagon (combination)

1
graded findings
1
effect domains
Evidence spread
High evidence 0Moderate evidence 1Low evidence 0Very low evidence 0

GLP-1 + Glucagon Co-infusion is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
GLP-1 + Glucagon Co-infusion MARKETED
Appetite and food intake Decrease
Moderate evidence

Co-infusion of individually subanorectic doses of GLP-1 and glucagon in humans reduced food intake ~13% and raised energy expenditure ~53 kcal/day while protecting...

Cegla J et al., Diabetes 2014;63(11):3711-3720 Source
Full findingCo-infusion of individually subanorectic doses of GLP-1 and glucagon in humans reduced food intake ~13% and raised energy expenditure ~53 kcal/day while protecting against glucagon-induced hyperglycaemia. Combination (GCGR+GLP-1R) intake datum — the glucagon-arm contribution cannot be isolated; subanorectic glucagon by design contributes little alone (intake reduction most plausibly GLP-1-led).
PopulationHealthy/overweight humans, n=13 crossover
Fundingacademic-UK public (Wellcome Trust / MRC / NIHR / BBSRC)
Scope limitssmall sample (N~13)
Comparatorssaline; GLP-1 alone; glucagon alone